Good results prompt Millennium to end Velcade trial

09/18/2007 | Forbes

Millennium Pharmaceuticals has decided to stop the Phase III trial of its cancer drug Velcade on positive results from combining the injectable treatment with other drugs. The company noted promising interim results in testing Velcade in combination with the chemotherapy drug melphalan and the corticosteroid prednisone among newly diagnosed multiple myeloma patients.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC